FDA Clears iPSC Therapy for Phase III as Regenerative Medicine Advances
The FDA has cleared Gameto’s iPSC-based therapy, Fertilo, for a Phase III clinical trial, marking a significant step in reproductive medicine. Meanwhile, a gene therapy for retinitis pigmentosa moves forward in Europe, and USC researchers receive a $6 million grant for glioblastoma therapy development.
